AI Analysis | Feedback

Here are 1-2 brief analogies for ENvue Medical (symbol: FEED):

• Medtronic for advanced catheter protection.
• A specialized Boston Scientific developing innovative solutions for catheter care.

AI Analysis | Feedback

• UroShield™: A catheter-based medical device utilizing low-intensity, surface acoustic wave technology.
• NG-Shield™: A catheter-based medical device utilizing low-intensity, surface acoustic wave technology.

AI Analysis | Feedback

ENvue Medical (symbol: FEED), formerly NanoVibronix Inc., is a medical device company that develops and manufactures catheter-based products like UroShield™ and NG-Shield™ devices. Given the specialized nature of these medical devices, the company primarily sells to other companies within the healthcare supply chain rather than directly to individuals.

Its major customers are typically:

• Healthcare Distributors: ENvue Medical partners with medical product distributors who then sell the devices to hospitals, clinics, and long-term care facilities. While the company's specific major distributors can vary and are not always consistently disclosed in public filings, a notable historical distribution partner for the U.S. market has been Medline Industries, Inc. Medline Industries, Inc. is a large, privately held medical supply company.
• Healthcare Providers/Systems: Ultimately, the end-users of ENvue Medical's products are healthcare institutions such as hospitals, urgent care centers, and long-term care facilities, which procure these devices through distributors or sometimes directly from the company.

AI Analysis | Feedback

AI Analysis | Feedback

Doron Besser, M.D. Chief Executive Officer

Dr. Doron Besser assumed the role of Chief Executive Officer of NanoVibronix (now ENvue Medical, Inc.) in June 2025. Prior to this, he served as the Chief Executive Officer of ENvue Medical, which NanoVibronix acquired on February 14, 2025. His appointment followed a strategic pivot for the company, shifting its core focus to the ENvue® feeding-tube placement system.

Rita Silberberg Executive VP of Finance and Chief Accounting Officer, Corporate Secretary

Rita Silberberg was appointed Executive Vice President of Finance and Chief Accounting Officer, as well as Corporate Secretary, in July 2025. She brings over 15 years of leadership experience in corporate finance, legal-structural planning, and international tax strategy. Before joining ENvue Medical Israel Ltd. in 2022, Ms. Silberberg served as Chief Financial Officer at Gravity Creative Space from 2013 to 2022. Her career also includes a role as Director of Finance and Project Manager at Ernst & Young from 2002 to 2005.

Dr. Harold Jacob, M.D. Chief Medical Officer

Dr. Harold Jacob is a co-founder of NanoVibronix (now ENvue Medical, Inc.), which was established in 2003. He has served as Chief Medical Officer since March 2014 and as a director since September 2003. From the company's inception in September 2003 until March 2014, Dr. Jacob held the position of Chief Executive Officer. Since 1999, he has been the president of Medical Instrument Development Inc., a firm that offers consulting services to start-up and early-stage companies and patents its own medical devices. Dr. Jacob previously served as Director of Medical Affairs at Given Imaging, where he played a key role in the development and launch of the Given Imaging Pillcam™. He also formerly served as a director for Oramed Pharmaceuticals Inc.

David Johnson Chairman of the Board

David Johnson was appointed Chairman of the Board of ENvue Medical, Inc. in December 2025. No further detailed background information related to founding or managing other companies, selling companies to acquirers, or a pattern of managing private equity-backed companies is readily available in the provided sources.

AI Analysis | Feedback

Here are the key risks to ENvue Medical (symbol: FEED):

1. Financial Instability and Reliance on Capital Raises: ENvue Medical, formerly NanoVibronix, Inc., faces significant financial challenges, operating with negative profitability and substantial net losses. As of late 2025 and early 2026, the company reported negative net income, negative EBITDA, and negative operating income, reflecting a pre-profitability, high-R&D-expense stage. Its liquidity is weak, with a low current ratio, meaning current assets barely cover short-term liabilities, and the company has experienced negative cash flow from operations. Management has expressed concerns about the ability to continue operations without additional capital, and there is substantial doubt about the company's ability to continue as a going concern unless successful commercialization of its products is achieved. The company has engaged in reverse stock splits and public offerings to bolster its stock price and raise capital, but continued reliance on capital raises poses a significant dilution risk to existing shareholders.
2. Regulatory Approval and Market Acceptance for Key Products: The company's ability to generate consistent sales and achieve profitability heavily depends on securing and maintaining regulatory approvals for its medical devices, particularly for its proprietary Surface Acoustic Wave (SAW) technology products like UroShield™ and PainShield®, and its newly emphasized ENvue® feeding-tube placement system. While ENvue Medical's ENvue system is 510(k) FDA-cleared for adult use and UroShield™ has CE mark certification, the company is still seeking U.S. Food and Drug Administration (FDA) approval for UroShield. Delays or complications in product implementation, along with intense competition from established medical device companies with deeper pockets and broader distribution networks, pose significant hurdles to market acceptance and commercial success.
3. Operational and Integration Risks Post-Merger: ENvue Medical completed a merger with ENvue Medical Holdings LLC in February 2025, which has significantly impacted its strategic direction and revenue flows. The company has since shifted its primary focus to scaling the ENvue feeding-tube placement system. Integrating a new business and product line adds complexity and execution risk, requiring successful commercialization of the ENvue system to drive future growth. Challenges include managing increased sales costs and operating expenses associated with scaling operations post-merger, which have impacted gross margins and led to increased net losses.

AI Analysis | Feedback

AI Analysis | Feedback

ENvue Medical (symbol: FEED), formerly NanoVibronix Inc., offers products primarily in the urinary catheter and feeding tube navigation markets.

The addressable market for ENvue Medical's main products is as follows:

• UroShield™: The global urinary catheters market, which UroShield™ addresses, was valued at approximately USD 6.17 billion in 2024 and is projected to reach USD 10.93 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2033. North America held the largest revenue share of 34.97% in this market in 2024.
• NG-Shield™: The company's "NG-Shield™" devices are related to its ENvue™ Navigation Platform, which is a minimally invasive electromagnetic navigation system for placing feeding tubes. A specific addressable market size for feeding tube navigation systems or "NG-Shield™" was not identified in the search results. Therefore, the addressable market size for this product is null.

AI Analysis | Feedback

ENvue Medical (symbol: FEED) anticipates several key drivers for revenue growth over the next two to three years, primarily stemming from its strategic shift and product advancements:

1. Expansion of the ENvue™ Navigation Platform: Following its rebranding, ENvue Medical is strategically focused on scaling hospital utilization of its ENvue™ feeding-tube placement system. The company aims to strengthen its commercial footprint and build a comprehensive enteral-feeding ecosystem around the ENvue platform, with potential future expansion into pediatric and vascular access applications.
2. Increased Market Penetration and Regulatory Approvals for UroShield™: The UroShield™ device, designed to prevent catheter-associated urinary tract infections (CAUTIs), is expected to drive revenue growth through broader market adoption. The company is pursuing FDA clearance in the United States and is leveraging its existing CE Mark approval and UK NHS reimbursement approval to expand its presence in global markets. Strong clinical data demonstrating significant reductions in CAUTIs supports this growth potential.
3. Strategic Commercial Partnerships and Distribution Agreements: To enhance its market presence and accelerate product adoption, ENvue Medical is actively pursuing strategic partnerships and distribution agreements. These collaborations are crucial for expanding the reach of both the ENvue platform and other proprietary products.
4. Development and Commercialization of New Products: The company's ongoing product pipeline, including potential "NextGen Prototypes" and the development of additional products within its proprietary low-intensity surface acoustic wave (SAW) technology and the broader enteral-feeding ecosystem, represents another driver for future revenue.

AI Analysis | Feedback

Share Issuance

• ENvue Medical, formerly NanoVibronix, Inc., completed a $2.0 million registered direct offering in December 2025, selling shares at $7.01 each.

Outbound Investments

• In February 2025, NanoVibronix, Inc. acquired ENvue Medical Holdings, Corp., a company specializing in electromagnetic navigation technology for enteral feeding tube placement. This acquisition led to the renaming of NanoVibronix, Inc. to ENvue Medical, Inc. in December 2025, reflecting a new strategic focus on the ENvue feeding-tube placement system.